Bemotuzumab
SCLC, Extensive Stage
Tianjin Medical University Cancer Institute and HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the SCLC, Extensive Stage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 1/2 | B |
Lomustine Yayi He | Phase 2 | CCC |
abp1011t Shanghai AB PharmaTech Ltd. | Phase 2 | CCC |
Utidelone Henan Cancer Hospital | Phase 2 | CCC |
Olvi-Vec Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | Phase 1/2 | CC |
Oxodotreotide Peking University Cancer Hospital & Institute | Phase 1 | CC |
Same molecule, other indications
Bemotuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →